Navigation Links
Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Date:6/16/2008

including high levels of LDL, or bad cholesterol, low levels of HDL, or good cholesterol, and high triglyceride levels -- known collectively as mixed dyslipidemia. Though some drugs have marked effects on some of these parameters, existing treatments do not optimally treat all elements of this common condition.

About MBX-8025

Earlier testing of MBX-8025 has suggested that the drug has the potential to improve a number of different lipid parameters, and because the mechanism of action differs from already-marketed cholesterol-lowering agents such as statins, MBX-8025 may be ideally suited to combination therapy. The drug may also have an effect on insulin sensitivity and body weight, which could further boost its utility in treating the constellation of symptoms known as metabolic syndrome.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, currently being studied in a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Metabolex Initiates Phase 1 Trial of MBX-2982
2. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
6. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
7. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
8. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
11. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... DALLAS , June 3, 2015 ... report "Interventional Cardiology & Peripheral Vascular Devices Market ... Angiography Catheters, EVAR Stent Grafts, IVC Filters, Stents, ... by MarketsandMarkets, the Interventional Cardiology and Peripheral Vascular ... Billion by 2019 with a CAGR of 7.4% ...
(Date:6/3/2015)... June 3, 2015  SurgiQuest®, Inc. ("SurgiQuest", the ... for minimally invasive surgery (MIS) announced today that ... over 250,000 procedures.  Adoption has risen rapidly with ... year, driven by the company,s expansion from robotics ... geographic expansion to over 45 countries.   ...
(Date:6/3/2015)... , June 3, 2015 PillPack, the ... completed a $50 million round of financing led by ... Ventures, and Sherpa Ventures. The capital will be used ... team, and build retail pharmacies in US markets. ... launched a better, simpler pharmacy experience that folks absolutely ...
Breaking Medicine Technology:The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 2The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 3The Interventional Cardiology and Peripheral Vascular Devices Market Worth $26.72 Billion by 2019 4Rapid Procedure Growth With SurgiQuest's AirSeal System 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 2PillPack Raises $50 Million to Build Retail Footprint and Accelerate Growth 3
... The U.S. Food and Drug Administration is warning consumers again ... King International and sold by various companies, due to serious ... Shoulder Flex Massager is a personal massage device sold ... intended to provide users with a deep tissue massage to ...
... Pharmaceuticals, Inc. (Nasdaq: AMPE)("Ampio" or the "Company"), a company ... drugs and new molecular entities ("NMEs"), announced today that ... to sell an aggregate approximately 2,220,255 of shares of ... "Shares"), at a price per share of $4.25 in ...
Cached Medicine Technology:FDA: Do Not Use ShoulderFlex Massagers 2FDA: Do Not Use ShoulderFlex Massagers 3Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 2Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 Fourroux Prosthetics, ... Duluth, GA will celebrate its grand opening with a ... The first prosthetic center of its kind in the ... family unmatched care and outcomes through use of patented ... CPO & CEO of Fourroux Prosthetics, states, “Our goal ...
(Date:6/3/2015)... Minneapolis, MN (PRWEB) June 03, 2015 ... new wellness "events" programming module. With this highly ... up, run and report on many components of its ... service at no additional charge. , With this new ... (1) Integrate DE challenges, (2) Create participant surveys, (3) ...
(Date:6/3/2015)... On May 29, 2015, Health Canada announced ... which now permits the use of gluten-free claims for ... The MA is a prelude to an official regulatory ... aware that, unlike the unlimited use of oats in ... for gluten-free oat products sold in Canada. , ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Come on ... Relay , a 200-mile overnight relay beginning in Madison, ... Illinois on Saturday, June 13th. , For the 4th ... the Brainstormers will run to raise money for the ... of different members of the Neurosurgery staff from The ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 evigilo, ... mass-notification, multi-channel solutions, reported of its "behind-the-scenes" involvement ... past few months. Since March this year, an ... been inflicting the South-American country, putting millions in ... and gas into the atmosphere. "evigilo's technology, adopted ...
Breaking Medicine News(10 mins):Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 3Health News:4th Annual Ragnar Relay from Madison, WI to Chicago, IL Once Again Benefits Renowned Brain Aneurysm Foundation 2Health News:Thousands of Lives Saved, Millions Protected in Chile 2
... in a woman over the world with over million new ... early puberty, late menopause, and genetic mutations can be risk ... University Hospital in Brussels, states that younger woman have poorer ... are older than 45 yrs of age. According to researchers ...
... reports from government health officials and the World Health Organization, ... She is the virus’ first human victim, in a year ... Mon Puthy, had been in close proximity with sick and ... 40 miles west of Phnom Penh. According to WHO spokeswoman ...
... attempted to introduce a new mental health law after Michael ... her daughter Megan Russell// in 1998. ,Although Stone ... be detained under the existing Mental Health Act because his ... of the proposed new bill was to redefine ‘treatable conditions’ ...
... substantiated in yesterday’s ruling by the Sheriff, confirming the inadequacy ... suffered a large abscess. According to the sheriff’s ruling, the ... specialist. The hospital had failed in their duty to guide ... revealed that due to negligence of the staff at St ...
... of Rochester Medical Center have found that teenagers who have ... tried cocaine and 15 times more likely to have // ... products. ,"The study points to the ... teens are using herbal remedies and from there probe deeper ...
... to talk with their children about sex, said US scientists.// ... nine-month public awareness campaign on billboards, radio and television in ... sex. Everyone else is." ,Results of a telephone ... influenced them to talk to their children about sexual issues, ...
Cached Medicine News:Health News:Breast Cancer More Serious For Younger Patients 2Health News:New Twist To The Mental Health Law 2Health News:Using Herbal Products Heightens Substance Abuse Risk in Teens 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: